Table 4. Efficacy Through Day 150 Postdose

RSV-Associated Clinical End Point	Comparison	Clesrovimab				Placebo				Estimated Efficacy, % (95% CI)
		Participants	Cases	Total Follow-up Time, mo	Incidence Rate over 5 mo	Participants	Cases	Total Follow-up Time, mo	Incidence Rate over 5 mo	
MALRI	100 mg clesrovimab vs placebo	64	1	312.5	0.016	38	3	181.6	0.083	80.6 (–141.2 to 99.6)
	Combined[a] clesrovimab dose group vs placebo	143	3	703.0	0.021	38	3	181.6	0.083	74.2 (–92.9 to 96.5)
ARI	100 mg clesrovimab vs placebo	64	2	312.0	0.032	38	4	176.9	0.113	71.6 (–97.8 to 97.4)
	Combined[a] clesrovimab dose group vs placebo	143	8	689.7	0.058	38	4	176.9	0.113	48.7 (–132.8 to 86.3)
Hospitalization	100 mg clesrovimab vs placebo	64	0	315.2	0.00	38	3	182.0	0.082	100 (–39.7 to 100)
	Combined[a] clesrovimab dose group vs placebo	143	0	708.1	0.00	38	3	182.0	0.082	100 (37.8 to 100)

Full analysis set population.

Abbreviations: ARI, acute respiratory infection (this encompasses lower and upper respiratory infections); MALRI, medically attended lower respiratory infection; RSV, respiratory syncytial virus.

[a]Combined 20, 50, 75, and 100-mg dose groups.